Latest Us Operations News

Carbonxt has added four US waste-to-energy facilities to its Reworld supply agreement, lifting annual Powdered Activated Carbon volumes by about 25% from January 2027. The expanded contract pushes the company’s FY27 revenue expectation to at least 40% above FY26, while Kentucky remains outside the forecast.

PainChek has expanded its Sabra relationship from two initial facilities to 23 US communities across five operators, covering 808 contracted memory care licences. The immediate test is whether those contracts become implemented recurring revenue by the end of 2026.

Vitasora says its remote-care model is now functioning, with estimated September-quarter revenue of US$1.028 million and a September exit rate of about US$17,400 a day. The next test is execution: turning planned Care Coordinator hiring into sustained, reconciled revenue and operational break-even.

Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.

Decidr AI Industries delivered 99% revenue growth and a A$13.6 million annualised exit rate in FY26, but the company’s A$32.4 million loss and auditor-highlighted going concern uncertainty put funding at the centre of its next chapter. Management is targeting A$5 million in annualised savings while seeking to convert early AI deployments into recurring revenue.

Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Austal has received a non-binding indication of interest from a Wildcat Infrastructure-led syndicate to buy Austal USA for an enterprise value of US$1.25 billion to US$1.35 billion. The proposal is conditional on four weeks of due diligence, leaving the potential transaction at an early and uncertain stage.

Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.

Galilee Energy posted a $5.42 million loss for FY2026 amid heavy investment in its US Zydeco Gas Project and progressing the sale of its Australian Glenaras asset. The company is pivoting to US operations with drilling underway and a $3.5 million placement announced.

Titomic has raised A$16.5 million through an institutional placement priced at a 23.5% discount, aiming to scale its Huntsville facility and accelerate US growth. The company also advanced a US$10 million loan application with the Export-Import Bank and appointed aerospace veteran Jim Chilton to its board.